Cardioprotective effect of trimetazidine during thrombolytic therapy in patients with acute myocardial infarction.
We studied the cardioprotective effect of anti-ischemic drug trimetazidine in the thrombolytic therapy of acute myocardial infarction. Trimetazidine (60 mg/day) effectively inhibits lipid peroxidation and moderates reperfusion damage to the myocardium assessed by ECG, QRS index of damaged heart, and release of creatine phosphokinase into circulation.
Rebrova
T Yu
TY
Laboratory of Molecular and Cell Pathology and Genetic Diagnostics, Siberian Division of the Russian Academy of Medical Sciences, Tomsk, Russia. pva@ant.tomsk.ru
Lasukova
T V
TV
Afanas'ev
S A
SA
Perchatkin
V A
VA
Maksimov
I V
IV
Markov
V A
VA
D003326:Coronary Circulation; D003402:Creatine Kinase / Q000097:blood / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D009206:Myocardium / Q000378:metabolism; D015912:Thrombolytic Therapy; D013997:Time Factors; D016896:Treatment Outcome; D014292:Trimetazidine / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
D014665:Vasodilator Agents; D008315:Malondialdehyde; D003402:Creatine Kinase; D014292:Trimetazidine